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The connection between signaling pathways acti-
vating cancer-associated fibroblasts (CAFs) remains
tobedetermined.Metabolicalterations linked toauto-
phagy have also been implicated in CAF activation.
CSL/RBPJ, a transcriptional repressor that mediates
Notch signaling, suppresses thegeneexpressionpro-
gram(s), leading to stromal senescence and CAF acti-
vation. Deregulated GLI signaling can also contribute
toCAFconversion. Here,we report that compromised
CSL function depends on GLI activation for conver-
sion of human dermal fibroblasts into CAFs, sepa-
rately fromcellular senescence. DecreasedCSLupre-
gulates the expression of the ULK3 kinase, which
binds and activates GLI2. Increased ULK3 also in-
duces autophagy, which is unlinked from GLI and
CAF activation. ULK3 upregulation occurs in the
CAFs of several tumor types, and ULK3 silencing
suppresses the tumor-enhancing properties of these
cells. Thus, ULK3 links two key signaling pathways
involved in CAF conversion and is an attractive target
for stroma-focused anti-cancer intervention.
INTRODUCTION
Stepwise acquisition of genetic alterations is implicated in
epithelial tumor development, yet many of these changes can
be found in apparently normal tissues, pointing to the impor-
tance of concomitant stromal changes (Bissell and Hines,
2011; Hanahan and Weinberg, 2011; Martincorena et al.,
2015). Notch signaling controls cell-fate commitment, differenti-
ation, and tumorigenesis (Allenspach et al., 2002; Artavanis-Tsa-
konas et al., 1999; Dotto, 2009). While Notch tumor-suppressive
function in stratified epithelia is well established (Dotto, 2008),
recent evidence indicates an opposite role in stromal fibroblasts
(Hu et al., 2012; Junttila and de Sauvage, 2013; Procopio et al.,
2015). Specifically, the CSL/RBP-Jk protein (CSL), a transcrip-
tional repressor mediating Notch signaling, is key for the nega-2468 Cell Reports 20, 2468–2479, September 5, 2017 ª 2017 The Au
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Deletion of the CSL gene in the mesenchymal skin compartment
of mice results in multifocal keratinocyte tumor development
preceded by dermal atrophy, matrix alterations, and inflamma-
tion (Hu et al., 2012). CSL loss in primary human fibroblasts re-
sults in a similar CAF phenotype that is associated with a p53-
dependent program of cellular senescence (Procopio et al.,
2015). The concomitant downmodulation of CSL and p53 activ-
ities leads to the expansion of altered stromal fibroblasts and
cancer cells as seen in field cancerization, a condition of major
clinical significance consistent of multiple and recurrent tumors
(Dotto, 2014).
The Hedgehog (Hh) pathway is linked to the development of
several types of epithelial cancers (Rubin and de Sauvage,
2006). A paracrinemechanismhas been implicated inCAFactiva-
tion, with Hh ligands secreted by cancer cells activating the gli-
oma-associated transcription factors (Gli) in surrounding stromal
cells (Junttila anddeSauvage, 2013; TheunissenanddeSauvage,
2009). Interestingly, while this chain of events should enhance
tumor formation (Theunissen and de Sauvage, 2009), an opposite
restraining function of stromal Hh activation in pancreatic and
bladder cancer has also been reported (O¨zdemir et al., 2014;
Rhimetal., 2014;Shinet al., 2014).Mammaliancells express three
GLI proteins (Aberger andRuiz i Altaba, 2014). Under basal condi-
tions, glioma-associated transcription factor 2 (GLI2) is cleaved
into a transcriptional repressor, with Hh stimulation blocking this
process and converting it into an activator. Expression of gli-
oma-associated transcription factor 1 (GLI1) is then induced as
a signal amplifier. In Drosophila, the activation of GLI homolog
Cubitus interruptus (Ci) is well established (Ruel et al., 2003;
Wang et al., 2000), with a kinase (Fused) releasing it from an inhib-
itory complex (Costal2/SuFu) andpromoting its nuclear transloca-
tion. Inmammaliancells, themechanisms responsible forGLI acti-
vation are less understood. Recently, the unc-51-like-kinase 3
(ULK3), an inducer in human fibroblasts of autophagy (Young
et al., 2009), has been proposed to fulfill the role of Fused through
association and phosphorylation of GLI2 (Maloverjan et al., 2010;
Rubin and de Sauvage, 2006). Importantly, in cancer cells, GLI
proteins can also be activated by Hh-receptor-independent
mechanisms involving phosphatidylinositol 3-kinase (PI3K)/AKT
(Metcalfe and de Sauvage, 2011), mitogen-activated proteinthor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
kinase (MAPK)/ERK (Seto et al., 2009), S6K (Wang et al., 2012),
and KRAS activation (Nolan-Stevaux et al., 2009; Stecca et al.,
2007).
Recent evidence suggests that altered metabolic properties
of CAFs, resulting from increased autophagy/mitophagy and
associated shift to aerobic glycolysis, can contribute to their tu-
mor-enhancing properties (Kalluri, 2016; Martinez-Outschoorn
et al., 2017). How these processes relate to CAFs activation
remains to be determined. We report here an as-yet-unex-
pected link between the CSL and GLI signaling pathways,
with the ULK3 kinase as an attractive target for stroma-focused
anti-cancer intervention, controlling the CAF effector gene
expression program separately from the autophagy/mitophagy
processes.
RESULTS
CAF Conversion by Loss of CSL Function Depends on
GLI Activation
The conversion of normal stromal fibroblasts into CAFs is likely to
be a multistep process, with loss of CSL transcriptional repres-
sion inducing a large battery of CAF effector genes associated
with stromal cell senescence, as a fail-safe mechanism limiting
cancer/stromal cell expansion (Procopio et al., 2015). An un-
answered question is the possible integration of different
signaling(s) leading to CAF conversion. Like Notch/CSL, Hh-
GLI signaling is deregulated in tumor stroma and can contribute
to CAF activation (Junttila and de Sauvage, 2013; Theunissen
and de Sauvage, 2009). Under basal conditions, GLI2 is cleaved
into a transcriptional repressor, while block of this process coin-
cides with GLI2 activation and induction of GLI2 and GLI1
expression as signal amplifiers (Aberger and Ruiz i Altaba,
2014). We found that, in human dermal fibroblasts (HDFs), the
short repressive form of GLI2 was dramatically reduced, while
the full-length transcription-activating protein was induced by
shRNA-mediated CSL silencing (Figure 1A), at a time coinciding
with the induction of CAF effector genes but preceding that of
cellular senescence, (Procopio et al., 2015). In parallel, GLI1
and GLI2 expression was upregulated in HDFs and, to a similar
extent, also in human gingival fibroblasts (HGFs) (Figures 1B,
1C, and S1A).
The aforementioned findings are of clinical and functional
significance. Patient-derived CAFs have higher GLI2 levels
than HDFs, which are inversely related to CSL expression (Fig-
ure 1D). Global analysis of gene expression of HDFs versus
CAFs present notable similarities when compared to the
expression profile after downmodulation of CSL function in
HDFs (Procopio et al., 2015); thus, in our studies, we focused
on a limited number of CAF genes to characterize the mecha-
nism of HDF conversion to CAF. Functionally, induction of
CAF effector genes by CSL knockdown was blocked in
HDFs with concomitant GLI2 silencing (Figure 1E) or in mouse
embryo fibroblasts (MEFs) with disruption of the gli1 and gli2
genes (gli 1/2/) (Lipinski et al., 2008; Figures 1F and 1G).
Notably, upregulation of senescent effectors by CSL loss
was unaffected by GLI2 silencing, thus implicating GLI activa-
tion selectively in the induction of CAF effector genes (Figures
S1B and S1C).An essential property of fibroblasts with deleted or silenced
CSL is that they enhance the growth of adjacent cancer cells
(Procopio et al., 2015). To test whether these properties are
GLI dependent, we used a cancer/stromal cell expansion model
that we developed, based on mouse ear injections of weakly
tumorigenic squamous cell carcinoma (SCC) cells admixed
with fibroblasts with various genetic manipulations (Procopio
et al., 2015). We determined, every 3 days for 3 weeks, the
growth of EGFP-expressing SCC13 cells admixed with gli+/+ or
gli 1/2/MEFs, both with or without Csl silencing. As previously
reported for HDFs with CSL silencing (Procopio et al., 2015),
SCC13 cells admixed with gli+/+ MEFs with Csl knockdown
formed significantly larger lesions than controls (Figures 1H–
1J), while the tumor-enhancing effects of Csl silencing were
lost with MEFs with gli1/2 gene deletion (Figures 1H–1J and
S1E). Hence, our data indicate that CAF conversion of stromal
fibroblasts by CSL loss requires GLI activity.
ULK3 Is a Direct CSL Target Gene that Links CSL
Silencing to GLI and CAF Activation
In cancer cells, GLI proteins can be activated by Hh-receptor-
dependent and -independent mechanisms (Aberger and Ruiz i
Altaba, 2014). The ULK3 kinase was recently proposed to fulfill
the same role in mammalian cells as the Drosophila Fused in
GLI2 activation, through possible association and phosphoryla-
tion (Maloverjan et al., 2010; Rubin and de Sauvage, 2006). In
agreement with these studies, we confirmed that ULK3 and
GLI2 can be recovered by co-immunoprecipitation in ULK3-
overexpressing cells, in which activated phosphorylated GLI2
(Xing et al., 2014) was detected (Figures 2A and 2B). We also
determined the association of endogenous ULK3 and GLI2 by
proximity ligation assays (PLAs) in HDFs in which ULK3 expres-
sion was increased by serum starvation (Figures 2C and 2D).
Upon CSL silencing, levels of ULK3 expression were signifi-
cantly induced in several HDFs strains, as well as in HGFs, while
expression of two other family members, ULK1 and ULK2, was
unaffected (Figures 2E–2G and S2A–S2C). Notably, ULK3 was
also induced afterCsl silencing in MEFs with gli1/2 gene deletion
(Figures 2H and 2I), in which the induction of CAF effector genes
was blocked (Figures 1F and 1G). Bioinformatic analysis of the
5,000-bp promoter region of the ULK3 gene upstream of the initi-
ating ATG revealed the presence of three putative CSL binding
sites. Chromatin immunoprecipitation (ChIP) assays of HDFs
showed little or no binding of CSL to the first upstream site
(Site 1), while the other two were strongly bound, one upstream
of the transcription start site (Site2) and the other in the first intron
(Site3) (Figure 2J). Histone marks of active chromatin configura-
tion (H3K27ac and H3K4me3) were highly enriched at these sites
upon CSL knockdown (Figures 2K and S2D).
Upregulation of ULK3 by CSL silencing is of functional signif-
icance, as GLI activation and induction of CAF effector genes
were suppressed in cells with concomitant CSL and ULK3
knockdown (Figure 3A). Consistent with previous reports (Malo-
verjan et al., 2010), we found that the activation of GLI reporter
activation required ULK3 kinase activity in HDFs (Figure S2E).
In contrast, determinants of cellular senescence (CDKN1A,
CDKN2A, and CDKN2B) were induced by CSL loss also in
concomitance with ULK3 silencing (Figures S2F and S2G).Cell Reports 20, 2468–2479, September 5, 2017 2469
Figure 1. CAF Activation by CSL Silencing Depends on GLI Activation
(A) Immunoblot analysis of two HDFs strains with or without shRNA-mediated CSL silencing for 7 days with anti-GLI2 and g-tubulin antibodies. The arrow points
to the truncated GLI2 repressor form.
(B and C) qRT-PCR analysis of GLI1 and GLI2 expression in HDFs, with or without (B) siRNA-mediated or (C) shRNA-mediated CSL silencing. Data indicate
mean ± SEM, three HDF strains, n (experiments) = 5 for sicsl OL1/2; n (experiments) = 3 for shcsl #1; n (experiments) = 2 in two HDF strains for shcsl #2. *p < 0.05,
two-tailed unpaired t test. mean ± SD. Analysis of HGFs with or without CSL silencing is given in Figure S1A.
(D) Left: immunoblots with antibodies against indicated proteins of HDFs and CAFs. Right: immunoblot quantifications; data indicate mean ± SEM; n (HDFs) = 4;
n (CAFs) = 7. *p < 0.05, two-tailed unpaired t test.
(E) qRT-PCR analysis of the indicated genes in HDFs with or without CSL and GLI2 silencing as indicated. Data indicate mean ± SEM with two HDFs strains;
n (experiments) = 3; *p < 0.05, two-tailed unpaired t test. Immunoblot analysis verifying CSL and GLI2 silencing is given in Figure S1C.
(F) qRT-PCR analysis of the indicated genes in mouse embryo fibroblasts (MEFs) with gli1 and gli2 gene disruption (gli 1/2/) (Lipinski et al., 2008) versus wild-
type control (gli+/+), stably infected with aCsl silencing versus control lentivirus for 2 weeks. Data indicate mean ± SEM; n (experiments) = 3; *p < 0.05, two-tailed
unpaired t test.
(G) Immunofluorescence analysis of gli+/+ versus gli 1/2/MEFs with or without shRNA-mediated CSL silencing as in (F), with the indicated antibodies and DAPI
for nuclear staining. Scale bars, 60 mM for CSL and SMA and 30 mM for TNC.
(H–J) EGFP-expressing SCC13 cells were admixedwith either gli+/+ or gli 1/2/MEFs, stably infectedwith aCsl silencing or control lentivirus, followed by parallel
injections into contralateral ears of SCIDmice. (H) Images of combined bright-field and fluorescencemicroscopy of threemice per combination of cells, at days 1
and 21 after injection. (I) Increase of average fluorescence signals over time for all tumors per group. Quantification was achieved using ImageJ on images
acquired every 3 days for 21 days, as in Procopio et al. (2015), and normalized to day1 after injection. n (tumors gli+/+) = 4 for shctr and 5 for shcsl; n (tumors gli
1/2/) = 5 for shctr and 6 for shcsl. For gli 1/2+/+ MEF shctr versus shcsl, *p < 0.05; for gli1/2/ MEF shctr versus shcsl, N.S (not significant), two-tailed equal
variance unpaired t test. (J) Tumor volumes, measured as V = [(length3width2)3 0.5], after 24 days from injection of admixed cells are indicated in (I). Median and
SD are indicated. For gli+/+ MEFs shctr versus shcsl, *p = 0.0091; and for gli1/2/ MEFs shctr versus shcsl, N.S (not significant), unpaired samples, two-tailed
equal variance t test. Scale bars, 30 mm for day 1 and 5 mm for day 21. The quantification comparing the lesions (shcsl/shctr) formed in the same animal is in
Figure S1D.
See also Figure S1.Conversely, increased ULK3 expression by lentiviral infection
was sufficient to induce GLI and CAF marker genes (Figures
3B and 3C), with induction of the latter being suppressed in cells
with GLI2 silencing (Figure 3D).
An important property of CAFs is the ability to enhance prolif-
eration of neighboring cancer cells. In co-culture assays, prolif-
eration of skin-derived SCC (SCC13) cells was enhanced to a
much greater extent by HDFs with silencing of CSL individually
than in combination with ULK3 (Figures 3E and 3F). Thus,
ULK3 is a direct CSL target gene, which is required for GLI and
CAF activation by CSL downmodulation.2470 Cell Reports 20, 2468–2479, September 5, 2017CSL Silencing and Increased ULK3 Induce Cellular
Autophagy and Mitophagy Separately from GLI and CAF
Activation
Similarly to other ULK kinase family members, ULK3 can play a
key role in the initiation of autophagy (Russell et al., 2013; Young
et al., 2009). Consistent with the observed upregulation ofULK3,
CSL silencing in HDFs induced autophagy, as assessed by a
number of biochemical events, including processing of microtu-
bule-associated protein-1 light chain 3 (LC3) (Klionsky et al.,
2016), Beclin-1 phosphorylation (Russell et al., 2013), and down-
modulation of the p62 cargo and TOM20 mitochondrial proteins
Figure 2. ULK3 Is a Direct CSL Target Gene that Links CSL Silencing to GLI Activation
(A) Immunoblot with anti-GLI2 antibodies of HEK293 cells transfected with an ULK3-V5 tag-expressing versus empty-vector control (Mock) after immunopre-
cipitation with anti-V5 antibodies with total input (Tot) as loading control.
(B) Immunoblot of total HEK293 extracts after transfection as in (A), with antibodies against activated phospho-GLI2 (Ser149) (Xing et al., 2014), GLI2, and b-actin.
(C and D) Proximity ligation assays (PLAs) with antibodies against ULK3 and GLI2 of HDFs serum starved for 24 hr for upregulation of endogenous ULK3. Assays
without primary antibodies (no Ab) (C) or with cells with siRNA-mediated ULK3 silencing (D) were used for specificity controls. Red fluorescence puncta resulting
from juxtaposition of anti-ULK3 and -GLI2 antibodies were visualized by confocal microscopy with DAPI nuclear staining. Number of puncta per cell, n (cells) >
120 per condition; p < 0.05, two-tailed unpaired t test.
(legend continued on next page)
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Figure 3. ULK3 Activity Is Required for Induction of GLI1/2 and CAF Effectors by CSL Silencing
(A) qRT-PCR analysis of the indicated genes in HDFs with or withoutCSL andULK3 silencing individually and in combination. Data indicate mean ± SEMwith two
HDF strains; n (experiments) = 3; *p < 0.05, two-tailed unpaired t test. An immunoblot analysis verifying CSL and ULK3 silencing is shown in Figure S2G.
(B) qRT-PCR of the indicated genes in HDFs infected with ULK3-expressing versus empty-vector control lentiviruses. Results are expressed as folds of
expression over control, after b-actin normalization. n (strains) = 2.
(C) Immunoblot of HDFs infected with same viruses as in (B), with antibodies against the indicated proteins.
(D) qRT-PCRof the indicated genes in HDFs infectedwith an ULK3-expressing (ULK3) versus control (cont) virus for 1 week, thenwith or withoutGLI2 silencing for
48 hr (total, 9 days). Results are expressed as folds of expression in ULK3 overexpressing versus control.
(E) Cell counts of EGFP-SCC13 cells cultured for 4 days on well inserts with HDFs with or without CSL and/or ULK3 silencing in the bottom. Duplicate cultures
were photographed daily, and number of EGFP-SCC13 cells were quantified using ImageJ software. Data indicate mean ± SD.
(F) qRT-PCR analysis ofmki67 expression, normalized to b-actin, in SCC13 cells co-cultured for 4 days with two different HDFs strains with or without CSL and
ULK3 silencing as in (E). n (strains) = 2.
See also Figure S2.(Bingol et al., 2014; Klionsky et al., 2016) (Figure 4A). Induction of
these events was associated with an increase of autophago-
some formation, which occurred also in HDFs withCSL silencing(E) qRT-PCR analysis of ulk1-3 expression in HDFs with or without siRNA-med
(experiments) = 5, three HDFs strains; *p < 0.05, two-tailed unpaired t test. qRT-
shRNA-mediated CSL silencing are given in Figures S2A and S2B.
(F) Immunoblot analysis of HDFs with or without siRNA- and shRNA-mediated CS
HGFs with or without CSL silencing is given in Figure S2C.
(G) Immunofluorescence analysis of HDFs at various times (hours) from siRNA-m
(H) Immunoblot analysis of gli+/+ versus gli1/2/ MEFs with or without shRNA-m
(I) Immunofluorescence with anti-ULK3 antibodies of MEFs as in (H), Scale bar, 3
(J) Top: scheme of the human ULK3 gene around the transcription start site (re
binding sites (Site1, -2, -3) relative to the initiation codon (ATG) and non-binding r
with anti-CSL (CSL) or non-immune antibodies (immunoglobulin G; IgG) followed
Results are expressed as enrichment fold relative to input; mean ± SEM, using two
significant.
(K) Chromatin immunoprecipitation assays (ChIPs) at the CSL binding sites in of H
(H3K27Ac27 and H3K4me3) versus non-immune immunoglobulin G (IgG) (black
region. Parallel chromatin immunoprecipitation assays with anti-CSL antibodies o
strain are given in Figure S2D.
See also Figure S2.
2472 Cell Reports 20, 2468–2479, September 5, 2017treated with the lysosomal inhibitor Bafilomycin, indicative of
an enhanced ‘‘on rate’’ (Figures S3A–S3D). Cellular mitophagy
is a selective form of autophagy with a decreased number ofiated CSL silencing with b-actin normalization. Data indicate mean ± SEM: n
PCR analyses of HDFs and human gingival fibroblasts (HGFs) with or without
L silencing with antibodies against ULK3 and g-tubulin. Immunoblot analysis of
ediated CSL silencing with antibodies against ULK3. Scale bar, 30 mm.
ediated Csl silencing with antibodies against ULK3 and b-actin.
0 mm.
d arrow) and first non-coding exon with nucleotide position of predicted CSL
egions (NB4, -5, -6). Bottom: Chromatin immunoprecipitation assays of HDFs
by binding determination of the indicated regions of the ULK3 gene by qPCR.
HDFs strains; n (experiments) = 3; *p < 0.05, two-tailed unpaired t test; NS, not
DFs with or without CSL silencing, with antibodies against active histone marks
and white bars, respectively) for the CSL binding sites at the ULK3 promoter
f HDFs are shown (gray and white bars). Results obtained using a different HDF
Figure 4. CSL Silencing and Increased ULK3 Induce Cellular Autophagy and Mitophagy Separately from GLI and CAF Activation
(A) Immunoblot analysis with antibodies against indicated proteins of HDFs with or without CSL silencing with siRNAs for 48 hr (left panel) or shRNAs for 1 week
(right panel). Numbers refer to densitometric quantification (folds of induction) of phospho-Beclin1 in CSL-silenced versus control cells. Immunofluorescent
analysis of endogenous puncta formation with or without sicsl and of red-fluorescent-protein-expressing HDFs with or without sicsl and with or without
Bafilomycin are in Figures S3A–S3C. Western blot of LC3 processing with or without sicsl and with or without Bafilomycin is given in Figure S3D.
(B) Immunofluorescence analysis with anti-TOM20 antibodies or MitoTracker Deep Red FM staining (right and left panels, respectively) of HDFs with or without
CSL silencing with siRNAs for 3 days. Scale bar, 10 mm.
(C) Immunoblot analysis of HDFs with or without CSL silencing with siRNAs for 3 days using antibodies against indicated proteins.
(D) Lactate secretion in culture medium of three HDFs strains with or without siRNA CSL silencing for 3 days. Results are expressed as the ratio sicsl/sictr,
normalized for cell numbers. n (strains) = 3; *p < 0.05, one-sample t test.
(E) Immunoblot with antibodies against indicated proteins of HDFs infected with ULK3-V5-expressing versus control viruses (7 days) with or without Bafilomycin
(400 nM) (last 4 hr of the experiment).
(F) qRT-PCR of the indicated genes in two HDF strains infected with ULK3-V5-expressing versus control viruses. Results are expressed as relative folds of
expression over control, n (strains) = 2.
(G) Immunofluorescence analysis of HDFs infected with ULK3-V5-expressing versus control viruses, using antibodies against TOM20, LDH, PKM2 and V5-tag.
Scale bar, 30 mm.
(legend continued on next page)
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mitochondria leading to a metabolic shift toward aerobic glycol-
ysis (Martinez-Outschoorn et al., 2017). After CSL silencing,
both the mitochondrial TOM20 immunofluorescence signal and
mitochondrial labeling with MitoTracker were decreased (Fig-
ure 4B). Consistent with enhanced mitophagy and glycolytic
transition, HDFs with silenced CSL had enhanced expression
of pyruvate kinase isozyme 2 (PKM2) and lactate dehydrogenase
A (LDHA), two key enzymes responsible for lactate production
(Figure 4C) and higher lactate levels (Figure 4D). A similar
induction of autophagy, decreased mitochondria network, and
increased glycolytic switch were observed in HDFs with
increased ULK3 expression (Figures 4E–4I).
An important question is whether the aforementioned pro-
cesses are linked to induction of the CAF effector gene program
or proceed as parallel independent events. Indicative of the
second possibility, we found that the silencing of CSL induced
CAF effector genes to a similar extent in HDFs with or without
silencing of the autophagy-essential genes ATG5, ATG7, or
BECN1 (Figure 4J) and in MEFs with Atg5 gene knockout,
compared to wild-type MEFs (Figure S3E). Similarly, increased
ULK3 expression by lentiviral infection induced CAF effector
genes in HDFs with silenced ATG5 (Figure 4K). Thus, both CSL
silencing and ULK3 upregulation enhance autophagy, which is,
however, dispensable for CAF effector gene induction.
ULK3 as a Target to Suppress CAF Activation and
Cancer/Stromal Cell Expansion
An important question was whether ULK3 expression is
increased also in clinically occurring CAFs. Analysis of published
gene expression profiles of CAFs derived from head and neck
SCCs (HNSCCs) showed that expression of ULK3 and GLI is
consistently higher than in normal fibroblasts derived from
the same body site, with similar upregulation in CAFs from pros-
tate (Ashida et al., 2012) and breast (Finak et al., 2008) cancers
(Figures 5A and S4A).
In skin, laser capture micro-dissection (LCM) followed by qRT-
PCR analysis showed consistently increasedULK3 expression in
several SCC-adjacent stromal cells (in areas we tested as devoid
of macrophage and leukocyte contamination; Procopio et al.,
2015), relative to stroma areas of distant normal skin (Figure 5B).
Results were confirmed by immunofluorescence analysis,
showing a significantly higher number of ULK3-expressing fibro-
blasts (Vimentin-positive cells) in SCCs surrounding stroma
versus unaffected areas of same or different individuals (Figures
5C and S4B). Similarly upregulated ULK3 and GLI levels—with
concomitantly decreased CSL—were also found in CAFs iso-
lated from skin SCCs relative to normal dermal fibroblasts from
same or different individuals (Figures 5D–5F and S4C). Results
were further validated in a mouse model of actinic keratosis(H) Immunoblot analysis of HDFs infected as in (G), with antibodies against indic
(I) Lactate secretion in culture medium of two independent HDFs strains infecte
pressed as ratio over control, after cell number normalization. n (strains) = 3; *p <
(J) RT-PCR analysis of a-SMA (acta2) and tenascin (tnc) genes in HDF with or with
atg7, or becn1, as indicated. n (strain) = 2. RT-PCR analysis of CAF-effector gen
(K) qRT-PCR of the indicated genes in HDFs infected with an atg5-silencing viru
expressing and corresponding control viruses for 3 additional days (total, 10 day
See also Figure S3.
2474 Cell Reports 20, 2468–2479, September 5, 2017(AK) based on mesenchymal deletion of the Csl gene (Hu et al.,
2012). LCM and qRT-PCR analysis showed significant Ulk3 up-
regulation in stromal fibroblasts of skin lesions that developed in
these mice at 3 months of age, relative to distant unaffected skin
(Figure 5G).
To assess whether the observed increase in ULK3 expression
and GLI activation in CAFs is functionally linked to decreased
CSL, we infected these cells with a CSL-inducible lentivirus
that we previously showed to suppress CAF marker expression
(Procopio et al., 2015). As shown in Figure 5H, increased CSL
expression caused a significant downregulation of ULK3 and
GLI levels.
A much-needed development for cancer therapy is the identi-
fication of strategies affecting cancer stroma (Goruppi and
Dotto, 2013). We found that siRNA-mediated silencing of ULK3
in two different CAFs strains downmodulated key CAF effector
genes and decreased GLI1 and GLI2 expression (Figure S5A),
suggesting that ULK3 could be an attractive target to counteract
CAF activation. We tested this possibility by using the same can-
cer/stromal cell expansion assays discussed earlier, with parallel
injections, into mouse ears, of SCC13 cells admixed with
two different strains of patient-derived CAFs with or without
shRNA-mediated ULK3 silencing. As shown in Figures 6A and
S5B, ear lesions formed in the presence of CAFs with ULK3
knockdown were consistently smaller than those in correspond-
ing CAF controls. This was paralleled by a lower number of can-
cer cells positive for the p63 differentiation marker and reduced
ki67 proliferative index (Figure 6B). Importantly, keyCAFmarkers
such as a-Smooth Muscle Actin (SMA), Periostin (POSTN), and
Tenascin C (TNC) were expressed to a much lower extent in
lesions with ULK3-silenced CAFs than in corresponding con-
trols, with increased macrophage infiltration and lesser angio-
genesis, as assessed by antibodies against CD68 and CD31
markers, respectively (Figures 6C and S5C). These data indicate
that ULK3, whose expression is elevated in clinically derived
CAFs, is required for the tumor growth-enhancing activity of
these cells.
DISCUSSION
Genes with critical cell- and tissue-regulatory functions are
tightly controlled by the convergence of multiple positive and
negative signals. While a large number of CAF-effector genes
have been identified, an unanswered question is in regard to
the integration of different signaling pathways involved in their
control. In stromal fibroblasts, CSL represses senescence- and
CAF-effector genes, with induction of the first class of genes
occurring as the result of loss of CSL repression and increased
p53 activity (Procopio et al., 2015). We show here that relief ofated proteins. n (strain) = 2.
d with ULK3-V5-expressing versus control viruses for 7 days. Results are ex-
0.05, one sample t test.
out siRNA-mediated silencing ofCSL individually and in combination with atg5,
e upregulation after CSL shRNA in atg5+/+ and atg5/ MEFs is in Figure S3E.
s versus control for 7 days and subsequent infection with an ULK3-V5-over-
s). Folds of expression over control; data indicate mean ± SD; n (strain) = 2.
Figure 5. ULK3 Levels Are Elevated in CAFs
(A)ULK3 levels in published gene expression profiles of CAFs derived from head/neck SCC (Costea et al., 2013), prostate cancer (Ashida et al., 2012), and breast
cancer (Finak et al., 2008); head/neck, n = 7 CAFs and n = 5 healthy individuals; prostate cancer, n = 10 CAFs and n = 10 healthy patients; breast cancer, n = 111
CAFs and n = 12 healthy patients. Two class comparison t tests, *p < 0.05, NFs versus CAFs. Median, maximum (max), and (minimum (min) (vertical whiskers) are
represented. The levels of GLI1 and GLI2 expression in these gene sets are in Figure S4A.
(B) Laser capture micro-dissection (LCM) and qRT-PCR analysis of ULK3 expression, normalized to 36b4, of stromal cells surrounding SCC cells versus normal
skin cells from the same patient (n = 4). The captured stromal cells in the SCC areas, indicated as T-1 to T-5, were previously characterized as negative for
macrophage and leukocyte infiltration and downmodulated CSL expression (Procopio et al., 2015).
(C) Left: double immunofluorescence analysis of stromal areas of two patient-derived squamous cell carcinomas (SCCs) and normal skin (NS) from the same
individuals using anti-Vimentin (red) and anti-ULK3 (green) antibodies. Arrows point to cells double positive for vimentin and ULK3. Scale bar, 100 mm. Additional
images of SCCs and NS are in Figure S4B. Right: quantification of vimentin-positive cells also ULK3+ in stroma of 4 NS donors compared to 4 matched and an
additional 6 unmatched SCC patients. At least 100 cells were counted for each sample; ns (sample) = 10 for SCCs and 4 for NSs. *p < 0.05, two-tailed unpaired
t test.
(D) qRT-PCR analysis of the indicated genes in SCC-derived CAFs versus matched normal HDFs from the same patients. n (patients) = 3. *p < 0.05, two-tailed
unpaired t test.
(E) Left: immunoblotting with antibodies against ULK3, CSL, and b-actin of CAFs and HDFs from different individuals. Right: densitometric quantification;
mean ± SEM. n (strains) = 3. *p < 0.05, two-tailed unpaired t test. Immunoblot of additional four CAFs and two HDFs strains is shown in Figure S4C.
(F) Immunofluorescence analysis of CAF andHDF strains as in (E), with antibodies against ULK3 (green), Vimentin (red), andDAPI (blue) staining. Scale bar, 30 mm.
(legend continued on next page)
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Figure 6. Loss of ULK3 Suppresses CAF Tumor-Enhancing Properties
(A) EGFP-expressing SCC13 cells admixed with two different CAFs strains (CAFs #1 and #3) infected with an ULK3-silencing versus control lentivirus were
injected into contralateral ears of SCID mice. Left: representative bright-field and fluorescence images of three mouse ear pairs (#a, #b, and #c) 21 days after
injection. Right: tumor volumes after 21 days, measured as V = (length 3 width2) 3 0.5, grouped by CAF strain. Data indicate median ± SD. CAF1: shctr versus
shulk3, n (lesions) = 4 and 6, respectively; CAF3: shctr versus shulk3, n (lesions) = 5 and 4, respectively; unpaired samples, two-tailed equal variance t test. Scale
bar, 5 mm. Matched ear pair comparisons (shulk3/shctr) are given in Figure S5B. Efficiency of ULK3 silencing is addressed in Figure S5D.
(B) Left: immunofluorescence analysis of ear lesions formed by SCC13 cells admixedwith CAFswith or withoutULK3 silencing with antibodies against p63 or ki67
(green) and pan-keratin (red) for SCC cell identification. Right: quantification of double keratin and p63- or ki67-positive cells for 3 ear pair lesions, using ImageJ
and watershed segmentation of digitally acquired images. Data indicate mean ± SEM, n (animals) = 3; *p < 0.05, two-tailed unpaired t test. Scale bar, 200 mm.
(C) Top: immunofluorescence analysis of ear lesions in two animals formed by SCC13 cells admixed with ULK3-silenced versus control CAF1 with antibodies
against endothelial (CD31) andmacrophage (CD68) markers, tenascin C (TNC), a-smoothmuscle actin (SMA), and periostin (POSTN), with DAPI nuclear staining.
The presence of CAFs in the lesions was confirmed with anti-vimentin antibodies (VIM). Bottom: quantifications of fluorescence signal for 3 ear pair lesions, using
ImageJ software; data indicate mean ± SEM; n (animals) = 3; *p < 0.05, two-tailed unpaired t test. Scale bar, 200 mM. Higher magnifications for TNC and SMA are
shown in Figure S5C.
(D) Summary diagram of the process leading from normal fibroblast to CAF activation, with ULK3 as critical node, as discussed in the text.
See also Figure S5.CSL repression of CAF-effector genes is not sufficient for induc-
tion of their expression, for which activation of GLI1/2 transcrip-
tion factors is also required. Increased expression of the ULK3
kinase, which occurs in CAFs from various cancer types, pro-(G) RT-PCR analysis of ULK3 expression in three LCM-obtained normal and affec
Samples were previously characterized for other genes in Procopio et al. (2015).
(H) qRT-PCR analysis of the indicated genes, with 36b4 for normalization, in the
expression or an empty-vector virus with or without doxycycline for 3 days. n (C
See also Figure S4.
2476 Cell Reports 20, 2468–2479, September 5, 2017vides a link between compromised CSL function and GLI activa-
tion, which can occur in concert with other previously reported
Hh-receptor-dependent and -independent mechanisms (Met-
calfe and de Sauvage, 2011; Seto et al., 2009; Wang et al.,ted stromal areas in the skin of 3 month-old mice having the CSL gene deleted.
n (lesions) = 3.
same CAF strains as in (E), stably infected with a doxycycline-inducible CSL
AF) = 3; *p < 0.05, one-sample t test.
2012; Nolan-Stevaux et al., 2009; Stecca et al., 2007). Auto-
phagy can create a pro-tumorigenic microenvironment rich in
metabolic precursors directed from CAFs to tumors (Lisanti
et al., 2010; Zhao et al., 2013). As ULK3 is also an inducer of
this process, it provides an attractive target for stroma-focused
anti-cancer intervention to suppress combined aspects of CAF
activation.
CSL is endowed with an intrinsic transcription-repressive
function, and CAF-effector genes are induced as a conse-
quence of CSL downmodulation (Hu et al., 2012; Procopio
et al., 2015), as it can occur upon exposure to pro-carcinogenic
stimuli such as UVA or smoke-derived compounds (Menietti
et al., 2016). We show that loss of CSL transcription-repressive
function is, by itself, not sufficient for induction of these genes
and for the resulting tumor growth-enhancing activity of fibro-
blasts, for which GLI activation is needed. Aberrant activation
of Hh/GLI signaling has been implicated in up to one third of
all human cancers and is considered to be both a consequence
and a driver of tumor-stromal interactions (Gupta et al., 2010;
Ruiz i Altaba et al., 2002). Hh ligands have been implicated as
paracrine mediators of cancer development (Rubin and de
Sauvage, 2006). Earlier studies indicated that production of
these molecules by colon, pancreatic, and ovarian cancer cells
can promote tumor growth indirectly by activating Hh signaling
in surrounding stroma (Theunissen and de Sauvage, 2009).
However, recent evidence points to a restraining role of Hh
stimulation in pancreatic and bladder cancer stroma (O¨zdemir
et al., 2014; Rhim et al., 2014; Shin et al., 2014). In our own anal-
ysis of multiple HDFs, strains with or without CSL silencing, and
skin-derived CAFs versus matched and unmatched controls,
expression of Hh ligands was variously modulated. Similar var-
iations were found in published profiles of CAFs from other can-
cer types. An attractive possibility is that, regardless of Hh
levels, GLI activation in stromal fibroblasts can occur through
increased activity of the ULK3 kinase, encoded by a direct
CSL target gene upregulated by CSL downmodulation.
ULK3 was recently proposed to fulfill the same central role in
mammalian cells as the Drosophila Fused kinase in GLI2 activa-
tion (Maloverjan et al., 2010). Besides confirming these results,
we found a detectable association of endogenous ULK3-GLI2
in HDFs and showed that increased ULK3 expression was
both required and sufficient for GLI and CAF activation. Sepa-
rately from this, we uncovered an interplay between CSL and
ULK3 in control of autophagy that may apply, with context-
dependent adjustments, to other cellular systems in which Notch
signaling has been pharmacologically implicated (Barth and
Ko¨hler, 2014; Chen et al., 2016; Song et al., 2015; Yao et al.,
2015). Importantly, while autophagy/mitophagy have been previ-
ously implicated inmetabolic reprogramming of CAFs (Kim et al.,
2011; Russell et al., 2013), our genetic evidence indicates that
they are not significantly involved in the gene expression pro-
gram leading to CAF activation.
A much-needed development for cancer therapy is the identi-
fication of strategies affecting cancer stroma (Goruppi and
Dotto, 2013). As in HDFs with CSL silencing and CAFs from
skin SCCs, analysis of publically available gene expression pro-
files indicated that ULK3 expression is elevated in CAFs derived
from several different cancer types, including HNSCC, prostatecancer, and breast cancer. Functionally, genetic suppression
of ULK3 in patient-derived CAFs was sufficient to inhibit CAF-
effector gene expression as well as GLI2 activation and sup-
pressed the growth-enhancing and pro-tumorigenic properties
of these cells on neighboring cancer cells. While similar effects
were observed with a compound reported to inhibit ULK3 kinase
activity, further translational studies await the identification of
compounds with greater specificity. Thus, ULK3 kinase, by
linking two key signaling pathways involved in CAF conversion,
represents an interesting target for stroma-focused anti-cancer
interventions.
EXPERIMENTAL PROCEDURES
Cell Manipulations
HDFs were prepared from discarded skin samples of abdominoplasty patients
at Massachusetts General Hospital (Boston, MA, USA) with institutional
approval (2000P002418), or were previously obtained (Procopio et al., 2015).
Conditions for culturing cells, viral infection, siRNA-mediated gene silencing,
qRT-PCR, and ChIP were previously reported (Brooks et al., 2014; Hu et al.,
2012). For derivation of CAFs and NFs, surgically excised discarded skin
SCC samples and non-affected skin samples were dissociated with Liberase
TL (Roche). For co-culture and in vivo approaches, skin SCC13 cells (Restivo
et al., 2011) were infected with an EGFP-expressing lentivirus (Tiscornia et al.,
2003). Each strain derived from a patient was identifiedwith a number, which is
indicated in the different panels.
Spontaneously immortalized MEFs with or without combined deletion of the
gli1 and gli2 genes (Lipinski et al., 2008) were infected with ULK3-silencing or
empty-vector control lentiviruses and selected with puromycin. After 2 weeks,
cells were analyzed by immunofluorescence for gene expression and were
then used for the in vivo studies.
Immunofluorescence, Autophagy Studies, and Cell Assays
Immunoblots and immunofluorescence analyses were performed as in (Kong
et al., 2010; Procopio et al., 2015). For immunofluorescence, cells were
seeded on coverslips, fixed in 3% paraformaldehyde (PFA), and processed
as in Kong et al. (2010). Immunohistochemistry of tumor and tissue sections
was performed as described previously (Brooks et al., 2014; Hu et al., 2012;
Procopio et al., 2015), and quantification of ki67 and p63 protein levels
was made using the watershed algorithm (http://imagej.nih.gov/ij/plugins/
watershed.html) and ImageJ (NIH). Quantification of all other tissue immuno-
fluorescence staining was performed using ImageJ.
Autophagosome evaluation studies were performed as in (Kong et al., 2010).
Two different strains of HDFs were infected with pHcRed1-LC3 encoding for
the far-red fluorescent protein (Clontech) fused to LC3.
Colorimetric determination of lactate was performed using an EnzyChrom
L-Lactate Assay Kit (BioAssay Systems). The cell culture supernatants of
HDFs with CSL silencing or overexpressing ULK3-V5 were collected after
3 days of culture. Each sample reaction was carried out in triplicate, and a
standard curve of lactate was used to determine the lactate concentration.
For mitochondrial labeling, HDFs with or without CSL silencing for 3 days
were pulse labeled with 100 nM MitoTracker Red FM (Thermo Fisher), fixed
with 3% paraformaldehyde (PFA) in PBS, and analyzed using confocal micro-
scopy (Zeiss Observer Z1) with Zen Pro 2.3 software. DAPI stained the nuclei.
The siRNA and shRNA sequences used are provided in Tables S1 and S2.
The oligonucleotides used in qRT-PCR are provided in Table S3. The oligonu-
cleotides used in ChIP experiments are provided in Table S4. A detailed list of
all the antibodies and the condition(s) used is in Table S5. Unprocessed orig-
inal scans of immunoblots are shown in Figures S6–S8.
Human Samples and LCM Experiments
Normal human skin samples and samples of SCCwere obtained at the Depart-
ment of Dermatology, Massachusetts General Hospital, as discarded parts not
needed for diagnosis. All samples were processed as approved by the institu-
tional review board. Matched normal skin and SCC paraffin samples used forCell Reports 20, 2468–2479, September 5, 2017 2477
LCM andRT-PCRwere provided by the Department of Dermatology, University
of Tubingen, with institutional review board approvals and informed consent, as
previously reported in Procopio et al. (2015). LCM was made using an Arcturus
XT micro-dissection system (Applied Biosystems), as in Hu et al. (2012) and in
Procopio et al. (2015). Gene expression was normalized to 36b4, and the
absence of contaminating leukocytes in the selected areas was previously
confirmed with CD45 oligos in qRT-PCR assays (Procopio et al., 2015).
Animal Studies
Experiment with gli1 and gli2/MEFs
Mouse ear injections with the MEFs were carried out in 8- to 10-week-old
female severe combined immunodeficiency (SCID) (CB17sc-m) mice (Ta-
conic), as in Procopio et al. (2015). EGFP-expressing SCC13 cells (1 3 105)
were admixed with equal numbers of MEFs (either gli+/+ or gli1/2/), with
shRNA-mediated silencing of CSL or a control. Cells were injected 5 mL per
site using a 33G microsyringe (Hamilton). Starting the day after injection,
the mouse ears were imaged using a fluorescent stereomicroscope (Leica
MZ-FLIII), every 3 days for 21 days. The mice were sacrificed after
24 days, and images of the ears were taken using bright-field and fluores-
cence stereomicroscopy.
Experiment with Patient-Derived CAFs
Mouse ear injections of cells were carried out in SCIDmice admixing EGFP-ex-
pressing SCC13 cells (13 105) with equal numbers of CAFs (strain #1 or strain
#3) infected with an ULK3-silencing lentivirus or empty-vector control. Mice
were sacrificed after 3 weeks.
All animal studies were approved by the Massachusetts General Hospital
Institutional Animal Care and Use Committee (2004N000170).
Statistical Analysis
Data are presented as mean ± SEM, mean ± SD, or ratios among treated and
controls, with two to three separate HDFs strains in independent experiments
as indicated in the figure legends. For gene expression and functional testing
assays, statistical significance of differences between experimental groups
and controls was assessed by two-tailed unpaired or paired t test and one
sample t test. p values < 0.05 were considered as statistically significant.
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